

U.S. Department of Justice

Drug Enforcement Administration FOI/Records Management Section 8701 Morrissette Drive Springfield, Virginia 22152

JUL 0 7 2016

Case Number: 16-00389-F

Subject: Records pertaining to the use of prepublication review processes in Intelligence Community agencies, etc.

Benjamin Good ACLU 125 Broad Street, 18th Floor

New York, New York 10004

Dear Mr. Good:

This letter responds to your Freedom of Information/Privacy Act (FOI/PA) request dated March 03, 2016, addressed to the Drug Enforcement Administration (DEA), Freedom of Information/Privacy Act Unit (SARF), seeking access to information regarding the above subject.

To fulfill your request for "policies, standards and guidance related to prepublication review; final legal analyses of past, present or proposed prepublication review requirements, final decisions of officials conducting prepublication reviews; statistics relating to prepublication-review....; titles, subject matters, and dates of works submitted for prepublication review; and information about enforcement proceedings instituted or contemplated on the basis of violations of prepublication-review requirements, including breach-of-contract actions, agency administrative proceedings, and civil or criminal litigation", our office forwarded a copy of your request letter to the Office of Chief Counsel (CC), the Office of Professional Responsibility (OPR), the Office of Congressional and Public Affairs (CP), Board of Professional Conduct (HRB), and the Office of Deciding Officials. Based upon all available information, we have determined that CC, OPR, HRB, CP and the Deciding Officials are the DEA components that may have records responsive to this portion of your request.

As a result of our search, the processing of your request identified certain materials that will be released to you. Portions not released are being withheld pursuant to the Freedom of Information Act, 5 U.S.C. § 552, and/or the Privacy Act, 5 U.S.C. § 552a. Please refer to the list enclosed with this letter that identifies the authority for withholding the deleted material, which is indicated by a mark appearing in the block next to the exemption. An additional enclosure with this letter explains these exemptions in more detail. The documents are being forwarded to you with this letter.

Case Number: 16-00389-F Page 2

Furthermore, your request for "correspondence with former agency employees (or their representatives) who have submitted materials for prepublication review since January 1, 2009", is not a reasonable description of a record. This portion of your request is so broad that it envelops every possible record that could or would be maintained by any of the 500 offices and/or decision units that currently comprise DEA. Correspondence, memoranda or other records of communications may be retrieved based upon the date, title or name, author, recipient, subject matter of the record, and the particular office(s) that may maintain the records. Moreover, our ability to locate a particular communication, in correspondence form, is limited, since correspondence files are generally maintained for a period of two (2) years. Thus, any correspondence, depending on the office to which it was sent, may no longer exist.

Similarly, communications also entails e-mails. DEA may retrieve information based upon a particular employee's e-mail account. However, to locate e-mails and/or correspondence electronically stored that may mention prepublication review, if they exist, requires a full text search of all DEA e-mail accounts, or a search of all documents previously stored as a result of requests for information. To retrieve e-mails or other records of communications pertaining to prepublication review requires additional particulars and information. Without identifying the sender and/or recipient, and/or a specific date would require a search of more than 400 servers and 15,000 e-mail accounts, using the search term, "prepublication review." Then each e-mail would have to be manually read to determine whether the contents reflect a "communication." Such a search would encompass a period of months and cause an interruption in normal DEA operations.

The rules and regulations of the Drug Enforcement Administration applicable to Freedom of Information Act requests are contained in the Code of Federal Regulations, Title 28, Part 16, as amended. They are published in the Federal Register and are available for inspection by members of the public.

For your information, Congress excluded three discrete categories of law enforcement and national security records from the requirements of the FOIA. See 5 U.S.C. § 552(c). This response is limited to those records that are subject to the requirements of the FOIA. This is a standard notification that is given to all our requesters and should not be taken as an indication that excluded records do, or do not, exist.

As you are aware, the FOIA provides for three categories of requesters. See 5 U.S.C. § 552(a)(4)(A)(ii). Department of Justice regulations define a "representative of the news media" as "any person or entity organized and operated to publish or broadcast news to the public." See Production or Disclosure of Material or Information, 80 Fed. Reg. 18099, 18111 (Apr. 3, 2015) (to be codified at 28 C.F.R. pt. 16.10(b)(6)). We have determined that you are making this request as a "representative of the news media," therefore; you will not be charged search fees.

In response to your request for a fee waiver, the Fee Waiver Committee met on March 31, 2016 and based on all available information, you have not met the requirements for a waiver of reproduction fees as stipulated in 28 C.F.R. § 16.11; therefore, your request for a fee waiver is denied. However, the costs for processing this request did not exceed the amount set out in 28 C.F.R. § 16.11(c), therefore, no fees will be charged for the processing of the enclosed response.

Case Number: 16-00389-F Page 3

If you are not satisfied with my response to this request, you may administratively appeal by writing to the Director, Office of Information Policy (OIP), United States Department of Justice, Suite 11050, 1425 New York Avenue, NW, Washington, DC 20530-0001, or you may submit an appeal through OIP's FOIAonline portal by creating an account on the following web site: https://foiaonline.regulations.gov/foia/action/public/home. Your appeal must be postmarked or electronically transmitted within 60 days of the date of my response to your request. If you submit your appeal by mail, both the letter and the envelope should be clearly marked "Freedom of Information Act Appeal."

If you have any questions regarding this letter, you may contact Government Information Specialist Deshelia S Wallace on 202-307-4264.

Sincerely,

Katherine L. Myrick, Chief

Freedom of Information/Privacy Act Unit

FOI/Records Management Section

Number of pages released:

Enclosures

APPLICABLE SECTIONS OF THE FREEDOM OF INFORMATION AND/OR PRIVACY ACT:

Freed	lom of Informa 5 U.S.C. 552		Privacy Act 5 U.S.C. 552a			
[] (b)(1)	[] (b)(5)	[] (b)(7)(C)	[] (d)(5)	[] (k)(2)		
[] (b)(2)	[X] (b)(6)	[] (b)(7)(D)	[](j)(2)	[](k)(5)		
[] (b)(3)	[] (b)(7)(A)	[] (b)(7)(E)	[] (k)(1)	[](k)(6)		
[] (b)(4)	[] (b)(7)(B)	[] (b)(7)(F)				

EXPLANATION OF EXEMPTIONS SUBSECTIONS OF TITLE 5, UNITED STATES CODE, SECTION 552

- (b)(1) (A) specifically authorized under criteria established by an Executive order to be kept secret in the interest of national defense or foreign policy and (B) are in fact properly classified pursuant to such Executive order;
- (b)(2) related solely to the internal personnel rules and practices of an agency;
- (b)(3) specifically exempted from disclosure by statute (other than section 552b of this title), if that statute-
- (A)(i) requires that the matters be withheld from the public in such a manner as to leave no discretion on the issue; or (ii) establishes particular criteria for withholding or refers to particular types of matters to be withheld; and (B) if enacted after the date of enactment of the OPEN FOIA Act of 2009, specifically cites to this paragraph. (b)(4) trade secrets and commercial or financial information obtained from a person and privileged or confidential;
- (b)(5) inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency;
- (b)(6) personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy;
- (b)(7) records or information compiled for law enforcement purposes, but only to the extent that the production of such law enforcement records or information (A) could reasonably be expected to interfere with enforcement proceedings, (B) would deprive a person of a right to a fair trial or an impartial adjudication, (C) could reasonably be expected to constitute an unwarranted invasion of personal privacy, (D) could reasonably be expected to disclose the identity of a confidential source, including a State, local, or foreign agency or authority or any private institution which furnished information on a confidential basis, and, in the case of a record or information compiled by criminal law enforcement authority in the course of a criminal investigation or by an agency conducting a lawful national security intelligence investigation, information furnished by a confidential source, (E) would disclose techniques and procedures for law enforcement investigations or prosecutions, or would disclose guidelines for law enforcement investigations or prosecutions if such disclosure could reasonably be expected to risk circumvention of the law, or (F) could reasonably be expected to endanger the life or physical safety of any individual;
- (b)(8) contained in or related to examination, operating, or condition reports prepared by, on behalf of, or for the use of an agency responsible for the regulation or supervision of financial institutions; or
- (b)(9) geological and geophysical information and data, including maps, concerning wells.

SUBSECTIONS OF TITLE 5, UNITED STATES CODE, SECTION 552a

- (d)(5) information compiled in reasonable anticipation of a civil action proceeding;
- (j)(2) material reporting investigative efforts pertaining to the enforcement of criminal law including efforts to prevent, control, or reduce crime or apprehend criminals;
- (k)(1) information which is currently and properly classified pursuant to an Executive order in the interest of the national defense or foreign policy, for example, information involving intelligence sources or methods;
- (k)(2) investigatory material compiled for law enforcement purposes, other than criminal, which did not result in loss of a right, benefit or privilege under Federal programs, or which would identify a source who furnished information pursuant to a promise that his/her identity would be held in confidence;
- (k)(3) material maintained in connection with providing protective services to the President of the United States or any other individual pursuant to the authority of Title 18, United States Code, Section 3056;
- (k)(4) required by statute to be maintained and used solely as statistical records;
- (k)(5) investigatory material compiled solely for the purpose of determining suitability, eligibility, or qualifications for Federal civilian employment or for access to classified information, the disclosure of which would reveal the identity of the person who furnished information pursuant to a promise that his/her identity would be held in confidence;
- (k)(6) testing or examination material used to determine individual qualifications for appointment or promotion in Federal Government service the release of which would compromise the testing or examination process;
- (k)(7) material used to determine potential for promotion in the armed services, the disclosure of which would reveal the identity of the person who furnished the material pursuant to a promise that his/her identity would be held in confidence.

· Memorandum

BEST AVAILABLE GOPY



Subject

Publications Review Board (FFS: 370-15)

Date 1987 115 1815

Meadquarters Office Heads Special Agents in Charge Country Attaches Thomas A. Constantine Administrator

It is very important that DEA's publications reflect the highest standards of quality and clearly articulate the goals, objectives and achievements of the agency. The establishment of a Publication Review Board will ensure that DEA publications reflect the best of DEA.

Our publications represent and demonstrate the significant dimensions of DEA investigations, operations and programs. Whether the intended audience is the public, state/local/Federal law enforcement entities, or Federal policymakers, it is critical that our publications are accurate, consistent with DEA policy, and professionally convey information. In the interest of streamlining, eliminating duplication, and fiscal constraint, it also is essential that, as an agency, we apply guidelines that will allow us to prioritize what we publish.

Consequently, effective July 1, 1995, I am establishing a Publications Review Board. Please be advised that all DEA field-or headquarters-generated publications, reports, pamphlets, brochures, posters, etc., intended for external audiences must be approved by this Board. The distribution of general interest documents (e.g., newsletters) intended exclusively for DEA audiences does not require the Board's review, but courtesy copies to the Board are required.

The Board will be comprised of senior representatives from the Operations Division, the Intelligence Division, the Operational Support Division, and the Office of Congressional and Public Affairs (CP), as well as field representation when possible. It will hold scheduled monthly meetings to expedite the publishing process, with supplemental meetings if required.

Instructions for submission are being developed and will be forthcoming. Questions regarding the specific aspects of this process may be directed to $CP \cdot s[b](\bar{a})$ who will serve as the technical advisor for this board.

PUBLICATIONS REVIEW BOARD 2009



	14 Februar	1
	for Confidences	1
	D. 13' A Sameous	ı
	for the factories	ı
ti sart	te sim at	
d was l	Minaset	
	,	

	TOPIB	APPROVED	SOURCE	CLASSIF	TITLE.	(c) Cabboras (c) CEASoncos (c) Castescous
; i j	11.25.0894	414 4th [28434	N	4.5	Microgram Jamary 2800	
61.	47.09.0994	ist to gaile	N.E	4	busings of exame trafficking turnigh Cluba	
64 %	10.29 38EK	161 11 1180F	Page .	4	I need Such Industry Transformation Drug Procured	. 3 t
191	147 56 50000	412 415 Janes	1	tr.	Mangan banalahiy ika Akir	1 14 1916 417
115	69.7.33% Septim	U. 13 2000)	78	11	National Learness Laboratory Edwardship Book Mid seen	M
+ 16.5	14.7 Jan 20839	113 M 218 80	Nt.	G	Mangran Telegrap 2009	143 [43]
: } ′	44.71 BRF4	03 US 21810	(1);	4	Prepared SPET Ingroduces Conglimenter	
164	49.8 4 C. DEMON	433 24 34849	91	14	Marshine March 9862	
iri	614 1 1 1989 P	11: (12 2031)	1111	13	Sational Prescription Prog. David Assessment	
111	14 1 1 380°	0.1 to 2009	SĪ	12	DIA Colorates Lanh Day 3499	
i t	mante lakes	644 C. Mass	110	LÍ	Universal Pide usp Connections with Leavisia Man Newton	the footness
4.1	04 17 Mira	115 18 3 RIV	€ 1 [3	ts	Street I destroid Visto Secret Compagn (DLAS 1A)	
13	61847. [1.146	115 115 Millia	5(4)	ų.	Wir on Progs Tresons Learned from 38 Years of Lighting	
} 	94 (1 Sam)	teh dir Jenina	1111	ir	Mari Paternen ed 6 Marchai	STATE OF STREET
1.4	err 17 Jenes	east da Bearea	SI	ξį.	Managam April 580	
151	特别 八大 海绵绿	the tel Joseph	No	ાં	Operation Herakthenigh the honous	
ŧ.	the fact femily	tick til Josep	\1	13	Microgram May 2009	
\$ ×	1965 Ests Denive	116: 15-2000	41	ta	14 A Chindestone Dong Labor they Cheming Propenti	
ş 4 à	de Carin Compte	47.15 Seed	51	£1	Maximum has 2009	
§ 3	H IN HER	11 f (2.4) (24 RP)	4.1[3	i.j	Proposint remo-pagers	
1	48 144 万田伊	08/07/2009	431)	ч	SILIS National Regional and Likel Patients - Mist Ar	60 x 1
- 4	11年 28 成長四	10X 1 (C) (2819)	(31)	14	Satural Correct Lab Information System (1968) Amount R	14461
7.4	* 1950 美元 "著籍的原	03 11 780	C3{1	ű	hospiopada il mitar propore	•
'4	5/8 1 2 3 mm	613] 1 Takto	Ş1.	13	Marigram July Mars	
- 4	G 2 TON THESE	(68) 5 (3 8 2 3	5.1	11	Passig Riperess with the DEA	
**	tia Na Stari	OR 25 THE	** 1%	41	Office of Adaption Management of agents	
: 1	444 3 \$ (MHH)	08 25 2009	€ +	11	Peter Caracias	
"R	883 888 DINES	एक हैं। इंक	- 41	11	14 A Agents in Algum Banke Space	
31	धंड १०३ - प्रत्रम	tieb bad Jahfen	- 71	44	Recognized their Constances the ophies	
161	tire i * Magara	the fit lines	M	a	Mangam Amar 2019	
3 4	44.0 [F. [2] [2] [44.4	संस्था है है। अस्तर	633.6	14	- United Day Scheduling Reviews Reputed by the L	4.4
4.7	10.04 2864	ter 18 Jahre	5 , j	\$4	Microgram September 200	
* 4	144 15 75 824	164 Jep 278333	1344	is	Special Report Medicaline	
11	34 To 2006	11 th Comp	113	U	TR Safety Bulletin, NOSH, X	
4.5	At 15 (1984)	\$ 77.48.8. (2.884.8.	1.131	· i	Six along Out Against Drag Expolication	
rén	· \$ +57 [A#43	1244 3469	7 C	18	V New Law Connects the Soft Station Supply Shoot	
* *	18 DR BRH	17 150 Jews	3111	, \$	1971 the town of Clean Maketing	

PUBLICATIONS REVIEW BOARD 2010



	то Рав	APPROYED	SOUNCE	CLASSIF	Tm.E	Classification in the rest of Contribution in the Contribution in
. 4 5	erg :å : '23664	01 i 4 linio	N		Marine Marine	
	1.5 1.5 5 # 24	0118.46 10	1331	() 13	Mempada December 100	
	418 3 1 53444	141 /7 Yele	SI	16	Change to admitted Change the Andrean of Days Merogram Change 1989	
- 1-1	61 91 3000	341 27 244ei	Si	11	Managian Navender Juri	
- 34	44 /46 /44 kd	ut 27 20to	Si	ti	Menegani Januar 1939 Menegani Januar 1930	
· át.	01.17.10(0)	01-78 (000	((ti.	the Straight Comming angle the	
. 4 .	0400.71146	0.7-36-2010	1 €	:4 14	The Blue Planet - International Pater Noticente & National Int.	
44%	111.19.1110	05.76 3010	SI	•	Mangaga Iching 2010	clinical c
171	187 314 31414	03 Se 3000	51	u u	549 Measurems louncil	
441	#11 (Sc. (\$11))	66 36 2000	81	4	Mehogom Marin 2010	
}	40.35.3034	04-02-5930	CPD	ti .	14 A Position on Manusco	
	H461 (40H	of the Miles	%}	45	Listle I Gas Rest Lease	
1 +	814 (FI /47)34	ed 21 Juni	SI	3+	Mayagasia - Apad 3010	
1	er eine Aufen	safety filler	OH	14	ADAS Mehros Report	
~,	HEAR MAN	03 (1.30)6	(14)	Ti-	Lose the Transa	
f;	414 12 (08)41	01-21 3910	SE	ij.	Cash not leave of the Contraction	
	45 1 - 2010	65 17 3010	SI	is .	Microgram May 2016	
÷-	145 1 5 Tebles	4210 REL 367247	N/ 1		Some of the Andre Leaster's Southern Burder	
1 - 2	1915 174 (CF)4+	One fit Bullia	SI	τέ.	Mistogram Jane 2010	
Fa.	414 70 744	0102 7680	*4111	13	lisertigating and Private group Helden Comparisoner Com-	£.
4	arm man	67 ns. Situ	4	13	Mangraph Igh Mill	*
17	ar or han	07 19 2010	6317	* 4	Methadone et pageri	
2.5	fr 1 1 1 Joseph	07 27 2010	6.51.6	4.7	SILIS brochages)	
	u* i. bail	19.7 3.7 July 6	CIE	¥r.	AALS & ASCI D Abstracts	
	61 to 1010	188 (44 201) 88	· 171 ·	Ł\$	DI A Position du Maritana desergi-	
€,	41% [· · · · (424)4	69 (B) (616)	M	\$3	Microphan August 2016	
- :	\$00 to 0 [43] \$10	क्षा है। स्वाहित	\$1	1.2	Microgram - September 2019	
18	224 1 - 1923 44	rei die biefie	r 3[3	31	MITS Annual Report 2009	
+	1tt 19 1 a	10 JS 2010	SI	t1	Microgram (Rinker 1010)	

October 28, 2010

Numbe	r/ To PRB/	Approved/	Sourc	ce/Classi	ification Title
O1.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
O1	01-06-11	01-10-2010	SE	u	Microgram Bulletin LE- January 2011
02.	02-09-11	02-28-2011	SF	u	Microgram Bulletin LE- February 2011 v 2
OB.	03-18-11	04-05-2011	SF	u	Microgram Bulletin LE March 2011 v 2
0.4	03-23-11	04-07-2011	ODE	u	Cathinone Derivatives
05.	03-03-11	05-02-2011	CPD	ti.	DEA Position on Marijuana
116	03-28-11	05-09-2011	TR	u	Interdiction Units at Transport Centers
07	01-21-11	05-17-2011	CPD	u	Drugs of Abuse Pamphlet
OS .	04-22-11	05-19-2011	SF	u	Microgram Bulletin LE April 2011
09.	05-11-11	05-23-2011	\mathbf{SF}	u	Anastrozole Vol 8 No 1 12-15
lu,	05-11-11	05-23-2011	SF	u	RTI-126 Vol 8 No 1 3-11
11.	05-17-11	05-31-2011	ODE	u	Diversion Control and Designer Drugs PPT
12	05-17-11	06-01-2011	ODE	u	Emerging Drugs of Concern
13	05-12-11	06-01-2011	OD	u	College on Problems of Drug Dependence PPT
1-4	05-19-11	06-08-2011	ODE	u	TFMPP (Molly) Drug Information Document
15.	05-19-11	06-08-2011	ODE	u	Levamisole Drug Information Document
16.	06-14-11	06-24-2011	SF	u	Microgram Bulletin May 2011
17.	06-24-11	07-07-2011	ODE	u	Emerging Drugs of Concern and Scheduling Actions
18.	06-17-11	07-12-2011	TR	ti.	Thermal Testing of Fire Resistant Fabrics
19	06-17-11	07-13-2011	SF	u	Microgram Article Levamisole-Lidocaine-Heroin
20.	05-23-11	07-18-2011	CPD	u	Just Think Twice Teachers Guide Revision
31	06-27-11	07-21-2011	ODE	u	NFLIS 2010 Mid-Year Report
33.	07-13-11	07-25-2011	SF	U	Microgram June 2011
23,	07-20-11	08-02-2011	ODE	u	Oxymorphone
34,	07-12-11	08-05-2011	OPS-I	louston	u DEA/Drug Law Enforcement in Austin, Texas
25.	05-18-11	08-08-2011	CPM	Ц	Trip to Oz [former DEA employee] ¹
.26	07-28-11	08-15-2011	SF	u	Microgram Article- Methamphetamine
27.	08-08-11	08-18-2011	SF	ti	Microgram Article PhenthylamineBy-Products
28	08-19-11	08-22-2011	SF	l.	Microgram Bulletin July 2011
29,	08-03-11	08-22-2011	CPD	u	Meth 101Teachers Guide PPT
30	08-30-11	09-13-2011	ODE	11	NFLIS User Guide
31.	09-08-11	09-21-2011	ODE	u	American College of Medical Toxicology PPT
32.	09-07-11	09-26-2011	SF	u	Microgram Bulletin LE August 2011
33.	09-06-11	09-27-2011	ODE	u	NFLIS Special Report- Synthetics
3.4	09-06-11	09-28-2011	ODE	u	NFLIS 2010 Annual Report
35	09-15-11	09-28-2011	SF	u	Microgram Bulletin LE September 2011
36	09-29-11	10-17-2011	SF	u	Microgram Journal Vol. 8 No. 2
37.	10-05-11	10-25-2011	FO	u	GOM US Banknote Regs Imp Mex Bulk Cash Laundering
38	10-21-11	11-02-2011	SF	l1	Microgram Bulletin LF October 2011
30	11-01-11	H-16-2011	CPD	u	Get It Straight Student Guide
40.	11-()1-11	11-16-2011	CPD	u	Get It Straight Facilitator Guide

Also Lyes of a Lawman by another former DEA employee

41	11-16-11	11-28-2011	SF	11	Microgram Bulletin 11-11
42.	12-09-11	12-22-2011	SF	u	Microgram Journal Article
43.	12-22-11	12-29-2011	SF	u	Microgram Bulletin December 2011

Eyes of a Lawman (former DEA employee) passed before decision on PRB/Formers made April-June 2011

Presently Circulating:

01 01-13-11 ODE u CEWG Meeting Abstracts [not used- was for use in a meeting but could not be cleared in time]

Numbe	er/To PRB/	Approved/	Soure	e/Class	sification Title
01.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
01.	01-12-12	01-23-12	ODE	u	Desomorphine One Pager
0.7	02-03-12	02-14-12	SF	ti	Microgram Bulletin January 2012
03.	02-21-12	02-22-12	ODL.	u	Pharmacy Theft Brochure Revision
04.	02-28-12	03-12-12	SF	u	Microgram Bulletin February 2012
05	03-08-12	03-12-12	SF	H	Microgram Journal Volume 9 Number 1
06	03-01-12	03-13-12	TR	u	First Responder Decontamination Procedures Paper
07	03-13-12	03-26-12	ÖDE	u	NFLIS 2011 Mid-Year Report
08	03-22-12	04-02-12	SF	u	Microgram Bulletin March 2012
09	04-19-12	05-04-12	CP1	U	Tradition of Excellence Video Script
10.	04-10-12	05-22-12	CPD	u	PPTs on Marijuana and Synthetic Drugs
11	05-01-12	05-22-12	ÖDE	u	NFLIS Special Report on Emerging Drugs
12.	05-16-12	05-31-12	CPD	u	Kratom Drug Fact Sheet
13.	05-22-12	06-04-12	SF	u	Microgram Journal Article Vol 9 Number 1
1-1	06-01-12	06-21-12	SF	u	April Microgram Bulletin LE
15.	06-25-12	07-09-12	ODED	u	Chemicals Used in the Clandestine Production of Drugs
16.	07-12-12	07-23-12	SF	u	Microgram Bulletin May 2012
17.	09-05-12	09-17-12	SF	u	Microgram Bulletin June 2012
18	09-05-12	09-17-12	SF	u	Microgram Bulletin July 2012
[9]	00-14-12	10-10-12	SF	u	Microgram Bulletin August 2012
20	()9-14-12	10-10-12	SF	u	Microgram Bulletin September 2012
u.,	10-04-12	11-06-12	ODE	u	NFLIS 2011 Annual Report
33	09-28-12	11-06-12	CPD	u	Growing Up Drug Free
23.	11-06-12	11-19-12		u	Synthetic Cannabinoids- UR 144, XLR 11
24.	10-25-12	11-20-12		u	Chemical Handlers Manual 2013 Revised Edition
25.	12-03-12	12-11-12	SF	u	Microgram Bulletin LE. November 2012
26.	11-28-12	12-17-12	ODE	U	Synthetic Cannabinoids and Cathinones - Update
27.	12-03-12	12-17-12	ODE	ŧı	NFLIS Special Report on ADD/ADHD Stimulants
28	11-28-12	12-20-12		U	Microgram Journal Articles Vol 9 Number 2
29.	12-03-12	12-21-12	SF	u	Microgram Bulletin LE October 2012

Not active:

Numb	oer/To PRB/	Approved/	Sourc	e/Clas	sification Title
01.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
01.	12-31-2012	01-10-13	SF	11	Microgram- December 2012
02.	01-22-2013	02-08-13	OD	u	AAFS Presentation on Emerging Drugs
113	02-19-2013	02-26-13	ODE	u	Drug and Chemical Information- Designer Synthetic Drugs
04	03-18-2013	04-02-13	ODE	u	NFLIS 2012 Mid-Year Report
11.1	04-02-2013	04-03-13	\mathbf{SF}	t1	NFLIS Synthetic Cannabinoids Slide
05	03-28-2013	04-04-13	SF	u	Microgram Journal Article- New Synthetic Cannabinoid
06	04-17-2013	04-26-13	SF	u	Synthetic Cannabinoids One Pager (AKB48/5F-AKB48)
07	06-12-2013	06-17-13	OD	(1	Synthetic Cannabinoids One Pager (PB-22 and 5F-PB-22)
08	06-25-2013	07-05-13	SF	u	Synthetic Drug Craze- Police Chief Magazine
(10)	06-26-2013	07-15-13	SF	U	Microgram Bulletin for January, February, March 2013
10	06-19-2013	07-17-13	extern	al u	Trip to Oz- Revised book for publication
11	07-17-2013		())	u	Acetylfentanyl- One Pager
12	06-28-2013		CPD	u	DEA Position on Marijuana
13	08-06-2013		OD	u	One Pager on three synthetic cathinones
14	08-12-2013		SF	u	Microgram Bulletin LE for April, May, June and July 2013
15.	09-03-2013		OD	11	NFLIS 2012 Annual Report
16	09-13-2013		SF	u	Microgram Journal Article - Black Cocaine
17.	10-03-2013		OD	ŧ1	Methyone One Pager
18.	10-17-2013		CC	u	Article: Searches Incident to Arrest in the Smartphone Age
19.	11-06-2013		SF	li	August, September Microgram Bulletin LF
20.	11-06-2013		SF	u	Microgram Journal Vol 10, Number 2 Cocaine/Cannabinoids
21	12-02-2013	12-24-13	CC	u	Night Vision Goggles
Not ac	live:				
[1]	01-30-2013		ΛĐ	u	NYT Op-Ed [*] Colombia, Mexico, Colorado, Washington: Source Countries for Illégal Drugs
02	08-01-2013		OD	u	Tox Talk Solicitation on Kratom (CC determined no PRB review needed)
1)3.	01-30-2013		СРМ	u	Update 2008-12 DEA History Book (approved however never received final version)
04.	02-11-2013		CPC	u	Congressional Fact Sheets (approved however never received final version)

Numl	ber/ To PRB/	Approved/	Sour	re/Cl:	assification Title
01.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
()]	01-27-2014	()2-()3-2()]4	(PD)	t1	DEA Drug Facts Cards 1-5
02.	02-06-2014	03-18-2014	CPD	1.1	Dangers and Consequences of Marijuana Abuse- update
(D) 3	02-28-2014	03-19-2014	OD	11	NFLIS Survey - Crime Laboratory Drug Chemistry Sections
()4	02-27-2014	03-21-2014	()[)	U	Journal Article: Synthetic Cannabinoid ADB-PINACA
()5	03-18-2014	03-31-2014	Atl	u	Marijuana Mania- ASA((6016)
06.	03-25-2014	04-07-2014	(1)	i.	Synthetic Cannabinoid AB-FUBINACA
()7	03-27-2014	04-11-2014	(PD	1.1	Updates to Drugs of Abuse
08_	03-27-2014	04-11-2014	OD	11	Phenazepam
1)()	04-11-2014	05-07-2014	()[)	u	NELIS Mid-Year Report and Two NELIS Flyers
1()	04-22-2014	05-15-2014	(PD	11	Dangers Consequences of Marijuana: Q2 2014 Update
11,	05-15-2014	06-03-2014	SI	U	Microgram Bulletins 10-13 to 2-14
12,	06-04-2014	()6-24-2()14	()[)	13	Drug Control- Scheduling Actions Under CSA PP1
13	06-18-2014	06-26-2013	(11)	U	Synthetic Drugs of Abuse - Update
1-400	07-02-2014	07-21-2014	OD	11	NFLIS Special Report: Synthetic Cannabinoids Cathinones
15	07-18-2014	08-14-2014	CPD	u	Marijuana Concentrates
16.	08-04-2014	08-18-2014	01)	1.1	2013 NFLIS Annual Report
17.	08-14-2014	09-17-2014	()()	11	Two OD PPT Presentations on CSA and DFA Scheduling
18	()9-24-2()14	1()-()1-2()14	())	u	One Pager Etizolam
10.	()()-3()-2()]4	10-27-2014	CPD	11	Prescription for Disaster (Pill Book)
2()_	09-25-2014	11-13-2014	extern	al u	Unlikely Allies
21.	11-04-2014	11-17-2014	('('	11	When Does Handeuffing Constitute Custody Article
27.	12-01-2014	12-15-2014	()])	13	Synthetics Article- New England Journal of Medicine
Not ac	tive:				
()] .	01-30-2013		ΛD	U	NY1 Op-Ed Colombia, Mexico, Colorado, Washington Source Countries for Illegal Drugs
()	01-15-2014		(141)	L1	DEA Drug Fact Cards 1-3 (Replaced by 1/27)
03	()4-3()-2()14		(PD	U	Marijuana Concentrates- resubmitted 7-18-14

Num	iber/To PRB/	Approved/	Sour	ce/Cl:	assification Title
O1.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
01	01-27-2014	02-03-2014	CPD	u	DEA Drug Facts Cards 1-5
0.7.	02-06-2014	03-18-2014	CPD	u	Dangers and Consequences of Marijuana Abuse- update
03	02-28-2014	03-19-2014	OD.	11	NFLIS Survey: Crime Laboratory Drug Chemistry Sections
(14	02-27-2014	03-21-2014	OD	u	Journal Article: Synthetic Cannabinoid ADB-PINACA
05.	03-18-2014	03-31-2014	Atl	u	Marijuana Mania- ASAC John Murphy
O(s	03-25-2014	04-07-2014	OD	u	Synthetic Cannabinoid AB-FUBINACA
07	03-27-2014	04-11-2014	CPD	11	Updates to Drugs of Abuse
OS	03-27-2014	04-11-2014	OD	u	Phenazepam
09_	04-11-2014	05-07-2014	OD	u	NELIS Mid-Year Report and Two NELIS Flyers
10.	1)4-77-7(1)4	05-15-2014	CPD	u	Dangers/Consequences of Marijuana: Q2 2014 Update
11	05-15-2014	06-03-2014	SF	u	Microgram Bulletins 10-13 to 2-14
1.2	06-04-2014	06-24-2014	()[)	u	Drug Control- Scheduling Actions Under CSA PP1
13	06-18-2014	06-26-2013	OD	u	Synthetic Drugs of Abuse - Update
14	07-02-2014	07-21-2014	OD	U	NFLIS Special Report: Synthetic Cannabinoids/Cathinones
15	07-18-2014	08-14-2014	(PD)	U	Marijuana Concentrates
16.	08-04-2014	08-18-2014	OD	u	2013 NFLIS Annual Report
17.	08-14-2014	09-17-2014	OD	u	Two OD PPT Presentations on CSA and DEA Scheduling
18	09-24-2014	10-01-2014	OD	u	One Pager Etizolam
10,	09-30-2014	10-27-2014	CPD	t1	Prescription for Disaster (Pill Book)
20.	09-25-2014	11-13-2014	extern	al u	Unlikely Allies
21.	11-04-2014	11-17-2014	CC	ŧi.	When Does Handcuffing Constitute Custody Article
22.	12-01-2014	12-15-2014	OD	u	Synthetics Article- New England Journal of Medicine
Not a	ctive:				
())	01-30-2013		AD	u	NYT Op-Ed. Colombia, Mexico, Colorado, Washington Source Countries for Illegal Drugs
02.	01-15-2014		CPD	ti	DEA Drug Fact Cards 1-3 (Replaced by 1/27)
03.	04-30-2014		CPD	tı	Marijuana Concentrates- resubmitted 7-18-14

Numb	er/ To PRB/	Approved/	Sourc	e/Cla:	ssification Title
O1.	01-07-2010	01-14-2010	SF	u	Microgram - December 2009 [example]
()]	02-24-2015	03-09-15	SF	u	Microgram Bulletin March, April 2014
0.2	03-02-2015	03-18-15	SF	Į1	Microgram Bulletin May, June 2014
()3	03-04-2015	03-19-15	CPD	u	Prescription Drug Fact Card
u4	03-17-2015	04-08-15	SF	tί	Microgram Bulletin July, August 2014
05.	03-18-2015	04-16-15	())	11	New England Journal of Medicine- Synthetic Cannabinoids
06.	03-12-2015	04-16-15	OD	11	2014 NFLIS Midyear Report
07	02-27-2015	04-17-15	NC	11	Operations-Intelligence Article- shirt on backwards
08.	04-07-2015	04-27-15	Lawle	ru	Active Shooter Article- FBI Law Enforcement Bulletin
09	04-13-2015	05-01-15	SF	u	Microgram Bulletin September, October 2014
10	04-28-2015	05-18-15	SF	u	Microgram Bulletin November, December 2014
11-	05-07-2015	05-22-15	SF	П	Microgram Articles- NBOM and Dipyrone-Heroin
12.	06-03-2015	06-22-15	CPD	u	Methamphetamine Drug Fact Card
13.	06-10-2015	06-22-15	CPD	ti	Prescription for Disaster
14	06-30-2015	07-16-15	ODE	li	NFLIS Special Report Opiates
15.	07-21-2015	08-10-15	SF	H	Microgram Article- Aceclofenac
16	08-18-2015	09-03-15	CPD	u	Heroin Laced with Fentanyl Trifold (resubmitted)
17	09-02-2015	09-22-15	SI	П	Microgram Bulletin January-June
18	09-03-2015	09-22-15	OD	u	Synthetic Cannabinoid Threat PP1
19	09-01-2015	09-22-15	OD	u	NFLIS 2014 Annual Report
20.	09-14-2015	09-28-15	SF	U	Microgram Bulletins July-August
21	10-20-15	11-06-15	CPD	u	Drug Fact Cards- Heroin, Spice, Marijuana
23	11-03-15	11-23-15	CPD	u	Prescription Drug Fact Card
23	12-14-15	12-31-15	OD	u	Benzodiazepines Special Report NFLIS
24	12-10-15	12-31-15	SF	u	Microgram Bulletins November-December 2015
25.	12-09-15	12-31-15	SF	u	Microgram Bulletins September-October 2015
26	12-31-15	01-11-15	CPD	u	Impaired Driving Publication
27	12-28-15	01-25-15	SF	LI.	Microgram Journal Article- Marijuana Analysis

Not active:

01 07-24-2015 CPD u Heroin Laced with Fentanyl Trifold (to be re-submitted)